Clinical Trial Search

Primary: Total Number of Participants With Negative Chlamydia Direct Fluorescent Antibody (DFA) Test Results After Oral Azithromycin Treatments — 27 participants

Primary: Change From Baseline in Ocular Itching at 14 Days — 2.17; 1.82 units on a scale

Primary: Ocular Itching Score at Day 14, 60 Minutes Into the Allergen Challenge — -1.550; -1.013 units on a scale

Primary: Percentage of Success to Prevent Pseudomembranes Relapse — 75; 81.8; 100; 100 percentage of eyes

Primary: Number of Participants Who Achieved Clinical Resolution at Visit 3 — 127; 123 Participants

Primary: Participants Who Achieved Clinical Resolution — 82; 74 Participants

Primary: One-year Incidence of Chlamydial and Gonococcal Infections in Women Who Receive Screening (Every 2 Months) and Treatment for Asymptomatic Bacterial Vaginosis as Compared…

Primary: Assess Microbiological Failure of Recommended Azithromycin and Doxycycline Regimens in Uncomplicated Chlamydia Trachomatis Infection in a Setting Where Repeat Exposure…

Primary: Clinical Cure at the Day 4 (EOT)/Exit Visit — 62.5; 50.6 percentage of subjects

Primary: Change From Baseline In Ocular Itching Frequency Score Using a 6-point Scale — 4.4; -3.4 Scores on a Scale

Primary: Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) - Mean Change in Total Score — -1.18; -1.17 score on a scale

Primary: Change in Ocular Itch Score From Baseline — -1.5; -1.5 units on a scale — p=0.532

Primary: Patient-Assessed Ocular Itching — 2.2; 2.2; 0.5; 0.5 units on a scale

Primary: Percentage of Patients With Clearing (Clinical Success) of Conjunctival Erythema and Conjunctival Discharge at Day 7 — 78.6; 84.4 Percentage of Patients

Primary: Number of Participants With Clinical Resolution Among Who Received SHP640 or Placebo on Day 5 — 111; 0; 95 Participants — p=0.127